Immune-stimulating soluble doxorubicin-conjugated complex
US11319341B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2020 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | Feb 20, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/1008
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.